Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. showcases a strong financial outlook through its innovative PREDATOR platform, which enables the design of conditionally activated molecules that target the tumor microenvironment, addressing limitations in traditional therapies. The company has reported positive developments in operational metrics, particularly with the ability to achieve significant progression in the design and application of its INDUKINE molecules, indicating ongoing advancement in its therapeutic pipeline. Furthermore, the company’s focus on stimulating both adaptive and innate immunity enhances its potential to capture market demand, positioning Werewolf Therapeutics favorably within the competitive biopharmaceutical landscape.

Bears say

The financial outlook for Werewolf Therapeutics appears negative due to multiple indicators of declining performance. The company has lowered its full-year same-store revenue growth guidance from a range of (0.35%)-1.15% to a new range of (0.20%)-0.40%, highlighting a deteriorating revenue forecast. Additionally, revenue has decreased by 30 basis points year-over-year while expenses have risen by 3.8%, resulting in a notable decline in net operating income by 2.6%.

Werewolf Therapeutics (HOWL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 4 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.